Neurimmune's management team has a proven track record in research and development and partnering.
Roger M Nitsch is a Founder and President of Neurimmune. A neuroscientist with a background in medicine, Roger M Nitsch is recognized as a key opinion leader in neurodegenerative disease research with more than 20 years of experience in Alzheimer’s disease research, and as a pioneer of disease-modifying therapeutic approaches for neurodegenerative diseases. The Potamkin prize winner, and Member of the German Academy of Sciences, directs the Institute for Regenerative Medicine (IREM) at the University of Zurich, Switzerland.
Jan Grimm is a neuroscientist with 15 years of experience in drug discovery and development in US and European biotech. Dr. Grimm co-founded Neurimmune in 2006 and served as the company's founding CEO. Before joining Neurimmune he led the Alzheimer’s disease research efforts at Rinat Neuroscience Corp. in San Francisco that was acquired by Pfizer in 2006. He received his PhD from Max Delbrück Center for Molecular Medicine and Humboldt University Berlin.
Dr. Michael Salzmann joined Neurimmune as COO in 2008. Prior to his appointment at Neurimmune, Dr. Salzmann held several positions as senior executive in the private and public sector. He has more than 15 years of industry experience in US and Europe, inter alia with Bruker and Roche. Dr. Salzmann graduated in physics and chemistry, and he was awarded a PhD in biophysics from the ETH Zürich, where he studied with Nobel Laureate Kurt Wüthrich at the Laboratory of Molecular Biology and Biophysics. In 2018, Michael Salzmann was awarded Corporate Professional of The Year by the Annual EMEA Corporate Development Awards in London, UK.
Dirk Schimkat is an economist with more than 16 years of experience in corporate finance in the consumer goods industry, telecommunications and healthcare. Before joining Neurimmune in 2008, he held a senior position at Beiersdorf’s La Prairie Group in Zurich, a global player in the selective beauty industry. Dirk Schimkat obtained his graduate degree in 1998 from the University of Basel, Switzerland.
Fabian Buller is an experienced biotech executive with 8 years of professional experience in biotech and pharma. Prior to joining Neurimmune in 2018, Dr. Buller served as Director New Ventures at Johnson & Johnson Innovation as well as Director Business Development of Covagen AG. He was instrumental in securing a number of major Biotech-Pharma deals including the sale of Covagen to J&J. Fabian Buller holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.